Swedbank AB decreased its holdings in shares of Savara Inc. (NASDAQ:SVRA – Free Report) by 17.6% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 700,000 shares of the company’s stock after selling 150,000 shares during the quarter. Swedbank AB owned about 0.34% of Savara worth $3,822,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Several other institutional investors have also recently made changes to their positions in SVRA. Polar Capital Holdings Plc purchased a new position in shares of Savara in the fourth quarter valued at $50,086,000. RTW Investments LP purchased a new stake in Savara during the 4th quarter worth about $35,893,000. VR Adviser LLC boosted its stake in Savara by 172.7% in the 2nd quarter. VR Adviser LLC now owns 8,884,263 shares of the company’s stock worth $20,256,000 after purchasing an additional 5,626,624 shares during the period. Marshall Wace LLP purchased a new position in Savara during the 4th quarter valued at about $27,496,000. Finally, Spruce Street Capital LP purchased a new position in Savara during the 4th quarter valued at about $14,539,000. Hedge funds and other institutional investors own 87.93% of the company’s stock.
Savara Price Performance
Shares of SVRA traded down $0.26 during trading hours on Friday, reaching $6.03. 1,720,421 shares of the company’s stock traded hands, compared to its average volume of 1,926,778. Savara Inc. has a 12 month low of $2.24 and a 12 month high of $7.01. The company has a current ratio of 13.47, a quick ratio of 13.47 and a debt-to-equity ratio of 0.17. The stock has a market cap of $1.24 billion, a PE ratio of -10.77 and a beta of 0.24. The firm’s 50 day simple moving average is $5.44 and its 200-day simple moving average is $5.56.
Analyst Ratings Changes
SVRA has been the topic of a number of recent analyst reports. Wall Street Zen raised shares of Savara from a “sell” rating to a “hold” rating in a report on Saturday, June 13th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Savara in a report on Tuesday, April 21st. HC Wainwright reiterated a “buy” rating on shares of Savara in a research note on Monday, March 16th. William Blair set a $10.00 price target on shares of Savara in a report on Monday, March 16th. Finally, Oppenheimer began coverage on shares of Savara in a report on Friday, April 24th. They issued an “outperform” rating and a $11.00 price target on the stock. One investment analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, Savara currently has an average rating of “Moderate Buy” and an average target price of $10.14.
Read Our Latest Analysis on SVRA
Savara Company Profile
Savara Inc (NASDAQ:SVRA) is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for rare respiratory diseases. The company specializes in in-licensing, advancing and potentially bringing to market novel treatments that address severe pulmonary conditions with high unmet medical need.
The company’s lead candidate, Molgradex (recombinant human granulocyte-macrophage colony-stimulating factor, or GM-CSF), is under regulatory review for the treatment of autoimmune pulmonary alveolar proteinosis (PAP), a rare lung disease characterized by the accumulation of surfactant.
See Also
- Five stocks we like better than Savara
- 3 Rare-Earth ETFs That Help Investors Balance Exposure and Risk
- Microsoft Bets on In-House AI to Cut OpenAI and Anthropic Costs
- Delta Air Lines Lives Up to Its Claims: Shares Can Keep Climbing
- This Dividend ETF Choice Could Shape Your Income Strategy Through 2026
Want to see what other hedge funds are holding SVRA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Savara Inc. (NASDAQ:SVRA – Free Report).
Receive News & Ratings for Savara Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Savara and related companies with MarketBeat.com's FREE daily email newsletter.
